U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C80H106Cl2N11O27P
Molecular Weight 1755.635
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 18
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TELAVANCIN

SMILES

[H][C@@]1(C[C@](C)(NCCNCCCCCCCCCC)[C@H](O)[C@H](C)O1)O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC3=C4OC5=C(Cl)C=C(C=C5)[C@@H](O)[C@]6([H])NC(=O)[C@H](NC(=O)[C@@H]7NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C8=CC=C(OC3=CC7=C4)C(Cl)=C8)C9=CC=C(O)C(=C9)C%10=C(C=C(O)C(CNCP(O)(O)=O)=C%10O)[C@H](NC6=O)C(O)=O

InChI

InChIKey=ONUMZHGUFYIKPM-MXNFEBESSA-N
InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1

HIDE SMILES / InChI

Description

TELAVANCIN (VIBATIV®) is a lipoglycopeptide antibacterial that is a synthetic derivative of vancomycin. It exerts concentration-dependent, bactericidal activity against Gram-positive organisms in vitro. TELAVANCIN (VIBATIV®) inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II. It also binds to the bacterial membrane and disrupts membrane barrier function. TELAVANCIN (VIBATIV®) is indicated for the treatment of adult patients with complicated skin and skin structure infections caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), or Enterococcus faecalis (vancomycin-susceptible isolates only). It is also indicated for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Staphylococcus aureus (both methicillin-susceptible and -resistant isolates). It should be reserved for use when alternative treatments are not suitable.

Originator

Approval Year

2009
359
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
VIBATIV

Approved Use

VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: Complicated skin and skin structure infections (cSSSI). Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus. VIBATIV should be reserved for use when alternative treatments are not suitable.

Launch Date

2013
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
93.6 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022110s016lbl.pdf
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TELAVANCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
747 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022110s016lbl.pdf
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TELAVANCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022110s016lbl.pdf
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TELAVANCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022110s016lbl.pdf
10 mg/kg single, intravenous
dose: 10 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
TELAVANCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24450506
Page: p.285
unhealthy, 62 ± 18.5
n = 751
Health Status: unhealthy
Condition: Nosocomial pneumonia
Age Group: 62 ± 18.5
Sex: M+F
Population Size: 751
Sources:
https://pubmed.ncbi.nlm.nih.gov/24450506
Page: p.285
Disc. AE: Acute renal failure, Electrocardiogram QTc interval prolonged...
AEs leading to
discontinuation/dose reduction:
Acute renal failure (1%)
Electrocardiogram QTc interval prolonged (1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/24450506
Page: p.285
15 mg/kg single, intravenous
Overdose
Dose: 15 mg/kg
Route: intravenous
Route: single
Dose: 15 mg/kg
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
healthy
Health Status: healthy
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
Other AEs: Dysgeusia, Nausea...
Other AEs:
Dysgeusia
Nausea
Vomiting
Injection site erythema
Headache
Macular rash
Red man syndrome
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1,5
unhealthy
n = 929
Health Status: unhealthy
Condition: Skin and skin structure infections caused by susceptible Gram-positive bacteria
Population Size: 929
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1,5
Disc. AE: Nephrotoxicity...
AEs leading to
discontinuation/dose reduction:
Nephrotoxicity (1.29%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1,5
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.9
unhealthy
n = 929
Health Status: unhealthy
Condition: Skin and skin structure infections caused by susceptible Gram-positive bacteria
Population Size: 929
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.9
Disc. AE: Nausea, Rash...
AEs leading to
discontinuation/dose reduction:
Nausea (1%)
Rash (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.9
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Skin and skin structure infections caused by susceptible Gram-positive bacteria
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1
Disc. AE: Clostridium difficile colitis, Electrocardiogram QTc interval prolonged...
AEs leading to
discontinuation/dose reduction:
Clostridium difficile colitis (all grades)
Electrocardiogram QTc interval prolonged
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Nosocomial pneumonia
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.4
Disc. AE: Hypersensitivity, Ototoxicity...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity
Ototoxicity
Superinfection
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.4
AEs

AEs

AESignificanceDosePopulation
Acute renal failure 1%
Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24450506
Page: p.285
unhealthy, 62 ± 18.5
n = 751
Health Status: unhealthy
Condition: Nosocomial pneumonia
Age Group: 62 ± 18.5
Sex: M+F
Population Size: 751
Sources:
https://pubmed.ncbi.nlm.nih.gov/24450506
Page: p.285
Electrocardiogram QTc interval prolonged 1%
Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24450506
Page: p.285
unhealthy, 62 ± 18.5
n = 751
Health Status: unhealthy
Condition: Nosocomial pneumonia
Age Group: 62 ± 18.5
Sex: M+F
Population Size: 751
Sources:
https://pubmed.ncbi.nlm.nih.gov/24450506
Page: p.285
Dysgeusia
15 mg/kg single, intravenous
Overdose
Dose: 15 mg/kg
Route: intravenous
Route: single
Dose: 15 mg/kg
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
healthy
Health Status: healthy
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
Headache
15 mg/kg single, intravenous
Overdose
Dose: 15 mg/kg
Route: intravenous
Route: single
Dose: 15 mg/kg
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
healthy
Health Status: healthy
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
Injection site erythema
15 mg/kg single, intravenous
Overdose
Dose: 15 mg/kg
Route: intravenous
Route: single
Dose: 15 mg/kg
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
healthy
Health Status: healthy
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
Macular rash
15 mg/kg single, intravenous
Overdose
Dose: 15 mg/kg
Route: intravenous
Route: single
Dose: 15 mg/kg
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
healthy
Health Status: healthy
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
Nausea
15 mg/kg single, intravenous
Overdose
Dose: 15 mg/kg
Route: intravenous
Route: single
Dose: 15 mg/kg
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
healthy
Health Status: healthy
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
Red man syndrome
15 mg/kg single, intravenous
Overdose
Dose: 15 mg/kg
Route: intravenous
Route: single
Dose: 15 mg/kg
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
healthy
Health Status: healthy
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
Vomiting
15 mg/kg single, intravenous
Overdose
Dose: 15 mg/kg
Route: intravenous
Route: single
Dose: 15 mg/kg
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
healthy
Health Status: healthy
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.8
Nephrotoxicity 1.29%
Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1,5
unhealthy
n = 929
Health Status: unhealthy
Condition: Skin and skin structure infections caused by susceptible Gram-positive bacteria
Population Size: 929
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1,5
Nausea 1%
Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.9
unhealthy
n = 929
Health Status: unhealthy
Condition: Skin and skin structure infections caused by susceptible Gram-positive bacteria
Population Size: 929
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.9
Rash 1%
Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.9
unhealthy
n = 929
Health Status: unhealthy
Condition: Skin and skin structure infections caused by susceptible Gram-positive bacteria
Population Size: 929
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.9
Electrocardiogram QTc interval prolonged Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Skin and skin structure infections caused by susceptible Gram-positive bacteria
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1
Clostridium difficile colitis all grades
Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Skin and skin structure infections caused by susceptible Gram-positive bacteria
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf
Page: p.1
Hypersensitivity Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Nosocomial pneumonia
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.4
Ototoxicity Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Nosocomial pneumonia
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.4
Superinfection Disc. AE
10 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 10 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.4
unhealthy
Health Status: unhealthy
Condition: Nosocomial pneumonia
Sources:
https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf
Page: p.4
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737
substrate
1037

inhibitor
1767
substrate
1217

inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2C19
1478

CYP3A4/5
278

CYP4A11
21
CYP1A2
1054

CYP2C19
991

CYP3A5
395

CYP4A11
119
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP4A11
25
 no
CYP3A4/5
335
 weak [IC50 14 uM]
no (co-administration study)
Comment: midazolam had no effect on PK of telavancin
Page: 111-113
CYP2D6
1891
 weak [IC50 35 uM]
CYP1A2
1692
 weak [IC50 40 uM]
CYP2C19
1553
 weak [IC50 54 uM]
CYP2C9
1819
 weak [IC50 89 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1054
 no
CYP2C19
991
 no
CYP2C9
1037
 no
CYP2D6
1217
 no
CYP3A4
1737
 no
CYP3A5
395
 no
CYP4A11
119
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ABI Chem
AC1MIWRX
BioSynth
T-1455
https://www.biosynth.com/products/biochemistry/culture-media-additives/products/T-1455.html
Chemieliva Pharmaceutical Co., Ltd
PBCM0532656
Phion Ltd
18583773
PubChem
3081362
https://pubchem.ncbi.nlm.nih.gov/compound/3081362
Smolecule
S544865
http://www.smolecule.com/products/s544865
THE BioTek
bt-283983
https://www.thebiotek.com/product/inhibitors/bt-283983
iChemical
EBD2322223
http://www.ichemical.com/products/372151-71-8.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Patents

Patents

20050113561
2
20090069534
2
7531623
2
8003755
2
WO2005042568A2
2

Sample Use Guides

In Vivo Use Guide
Complicated skin and skin structure infections: 10 mg/kg VIBATIV® by IV infusion over 60 minutes every 24 hours for 7 to 14 days. Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP): 10 mg/kg VIBATIV® by IV infusion over 60 minutes every 24 hours for 7 to 21 days.
Route of Administration: Intravenous
Name Type Language
TELAVANCIN
DASH   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
TELEVANCIN [VANDF]
Common Name English
TELEVANCIN
VANDF  
Common Name English
TELAVANCIN [MART.]
Common Name English
Telavancin [WHO-DD]
Common Name English
TELAVANCIN [MI]
Common Name English
TELAVANCIN [VANDF]
Common Name English
telavancin [INN]
Common Name English
VANCOMYCIN, N(SUP 3'')-(2-(DECYLAMINO)ETHYL)-29-(((PHOSPHONOMETHYL)AMINO)METHYL)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C61101
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
EMA ASSESSMENT REPORTS VIBATIV (AUTHORIZED: CROSS INFECTION PNEUMONIA, BACTERIAL)
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
NDF-RT N0000191281
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
WHO-ATC J01XA03
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
LIVERTOX 927
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
WHO-VATC QJ01XA03
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
Code System Code Type Description
DAILYMED
XK134822Z0
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
MESH
C487637
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
FDA UNII
XK134822Z0
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
INN
8504
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
WIKIPEDIA
TELAVANCIN
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
MERCK INDEX
m10527
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY Merck Index
LACTMED
Telavancin
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
CHEBI
71229
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
NCI_THESAURUS
C87603
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID10873383
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
DRUG CENTRAL
4116
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL507870
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
HSDB
8194
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
CAS
372151-71-8
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
SMS_ID
100000089642
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
DRUG BANK
DB06402
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
NDF-RT
N0000191280
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY Lipoglycopeptides [Chemical/Ingredient]
EVMPD
SUB26698
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
RXCUI
473837
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY RxNorm
PUBCHEM
3081362
Created by admin on Fri Dec 15 16:24:12 GMT 2023 , Edited by admin on Fri Dec 15 16:24:12 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of TELAVANCIN
SALT/SOLVATE (PARENT)
Structure of TELAVANCIN HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966